Have you noticed that one of RAC's applications was rejected because it was preceded by another patent lodged by Garner?
The examiner doesn't mention that Garner's patent has been assigned to RAC. I guess who owns a patent is irrelevant for the novelty examination. Interesting.
Ann: Zantrene highly effective in Melanoma preclinical study, page-176
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.055(3.61%) |
Mkt cap ! $250.5M | |||
| Open | High | Low | Value | Volume |
| $1.53 | $1.58 | $1.46 | $143.9K | 96.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 230 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 550 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |